JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

NCT06689917 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B-ALL
B-NHL

Interventions

DRUG: JY231 Injection

Sponsor

Tongji Hospital